Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.
The researchers observed that previous studies of dermatologic diseases have shown a much higher prevalence of depression in patients with CLE—in some cases double or triple that of the general population.
In this trial, treatment with apremilast showed significantly greater improvement in American College of Rheumatology 20% (ACR20) improvement response criteria and Health Assessment Questionnaire Disability Index (HAQ-DI) scores at week 16 for 20- and 30-mg twice-daily doses compared with placebo (Wells AF, et al. Rheumatology. 2018 Apr 4. Epub ahead of print).
Read Now